GlaxoSmithKline isn’t out of the weeds yet. The pharmaceutical company this week said the U.K. Serious Fraud Office has requested new information relating to an ongoing investigation, this time concerning third-party advisers engaged by the company.
The latest request relates to an ongoing inquiry that the SFO began in May 2014 into the group’s commercial operations in numerous countries, including China. “The SFO has requested information from the group on its commercial operations in these countries,” GSK said in its fourth quarter 2017 earnings report. “The group is cooperating and responding to these requests.”
The SFO inquiry followed investigations initiated by China’s Ministry of Public Security in June 2013, which resulted in a 2014 ruling, finding that GSK China Investment Co. (GSKCI) offered money or property to non-government personnel to obtain improper commercial gains, and GSKCI being found guilty of bribing non-government personnel.
“In the course of its ongoing inquiry, the SFO has requested additional information from the group regarding third-party advisers engaged by the company in the course of the China investigations,” GSK stated. GSK said it is cooperating and responding to these requests. It added that it has informed the U.S. Securities and Exchange Commission and U.S. Department of Justice of these matters and is responding to their requests for additional information.